TCT 2009: One-Year Results From Horizons – AMI study – show Two subset analyzes from the landmark HORIZONS – AMI trial, that the anticoagulant bivalirudin reduces major bleeding and cardiac death compared to the combination of heparin and a GP IIb / IIIa inhibitor in patients with ST – segment myocardial infarction , the disease of the left anterior descending artery , whereas in STEMI patients with the highest risk for death, bivalirudin also confers the greatest mortality benefit buy nolvadex online india .
The two abstracts to consider additional important information on the outcomes of patients with acute myocardial infarction . One part of the study focuses on primary angioplasty for acute anterior myocardial infarction with bivalirudin compared to unfractionated heparin plus GPIIb / IIIa inhibitors. This includes patients with massive heart attack and the effects of drug therapy in these patients. The other part of the study examines the benefits of bivalirudin therapy in high risk patients with with a heart attack. A research team led by Jochen W hrle, University of Ulm saw the clinical outcomes in patients with ST-elevation myocardial infarction , percutaneous coronary intervention of the left anterior descending coronary artery disease, non – LAD compared lesions. Investigators studied the effects of bivalirudin compared to unfractionated heparin plus a glycoprotein IIb / IIIa inhibitor on clinical outcomes in patients with STEMI undergoing primary PCI of the LAD subject. Nearly 50 percente was a significantly lower rate of myocardial infarction and non-significant trend towards fewer stent thrombosis and NACE compared rates with BIV therapy with UFH+ GPI, with no differences in ischemic TVR and stroke rates in the 2 groups.
Order to read the abstract of this product, securely click here.